Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with prednisolone and vincristine for reimbursement as a treatment option for the treatment of patients with relapsed / refractory low grade B cell Non Hodgkin's Lymphoma (NHL). The regimen states that rituximab is to be included for the treatment of CD20 positive patients.
This is written in the approval document as:
Treatment of patients with relapsed/refractory low grade B cell Non Hodgkin's lymphoma (NHL).
Citation
riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/r-cvp-v3-293.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Prednisolone, Rituximab, Vincristine |